Beyond Innovation S2: Daniel Legault, Antibe Therapeutics

(3:34)

Antibe Therapeutics is working to replace outdated inflammation treatments with a safer alternative

(2:50)

Dan Legault for Antibe Therapeutics

(5:51)

Antibe Therapeutics Inc. (TSXV: ATE) - 2019 TSX Venture 50

(1:)

Speaker Interview with Ana Stegic from Antibe Therapeutics

(41)

Antibe Therapeutics targets opioids with post-op pain drug

(4:13)

Antibe Therapeutics Inc. | Biotech Insights

(3:8)

Antibe Therapeutics Inc. (TSX:ATE) Investor Presentation

(16:16)

Dan Legault, CEO, Antibe Therapeutics Inc.

(4:42)

Antibe Therapeutics Inc. (TSX:ATE) Executive Presentation

(1:48)

Antibe Therapeutics Inc. (TSXV: ATE) - 2020 TSX Venture 50

(1:21)

Antibe Therapeutics (ATE) Deep Dive with CEO Dan Legualt

(50:3)

The world needs safer medicines - Antibe Therapeutics Inc. | Life Sciences Insight

(1:39)

Antibe Therapeutics finishes Phase 2 trial for ATB-346; results expected in weeks

(8:11)

Antibe Therapeutics (TSXV: ATE) New Listing -

(2:4)

Antibe Therapeutics (ATE) Pitch with Dan Legault CEO

(12:50)

CEORoadshow Interview with Daniel Legault, CEO of Antibe Therapeutics (ATBPF)

(11:39)

Antibe Therapeutics Virtually Opens The Market, February 8th, 2021

(20)

$ONCY Interview with Thomas Heineman, Chief Medical Officer, Oncolytics Biotech Inc.

(6:17)

Novartis mission

(1:16)

Antibe Therapeutics (ATE) CEO Dan Legault Discussion, Deep Dive, Q\u0026A - otenaproxesul pain trials

(43:21)